Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Recent & Breaking News (NDAQ:TLPH)

AcelRx Pharmaceuticals Adds New Board Member

PR Newswire December 11, 2013

Zalviso(TM) New Drug Application Accepted for Filing by FDA

PR Newswire December 2, 2013

AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

PR Newswire November 26, 2013

AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013

PR Newswire October 22, 2013

AcelRx Pharmaceuticals Announces Data Presentations for Zalviso(TM) at US and International Medical Meetings

PR Newswire October 15, 2013

AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso(TM) and its Proprietary Platform Technologies

PR Newswire October 8, 2013

AcelRx Pharmaceuticals Submits New Drug Application to the FDA for Zalviso(TM)

PR Newswire September 30, 2013

David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer

PR Newswire September 4, 2013

AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013

PR Newswire August 30, 2013

AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results

PR Newswire August 12, 2013

AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference

PR Newswire August 5, 2013

AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013

PR Newswire August 2, 2013

AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares

PR Newswire July 23, 2013

AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire July 18, 2013

AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire July 17, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ACRX, AMTG, FTK and GLUU

Accesswire July 15, 2013

Five Star Equities Issues New Research Reports on ACRX, ANAC, HILL and JNY

Accesswire July 9, 2013

AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes

PR Newswire July 2, 2013

AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events

PR Newswire July 1, 2013

AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013

PR Newswire June 21, 2013